A Case Report Links Rapid Semaglutide-Associated Weight Loss to an Uncommon Ear Condition

Most of the semaglutide literature tracks the outcomes GLP-1 receptor agonist research was designed to measure: body weight, HbA1c, cardiovascular events. A case report published this week in SAGE Open Medical Case Reports is a reminder that rapid, large-magnitude weight loss can also surface secondary physiological effects that have nothing to do with glucose or appetite signaling — in this instance, a mechanical change in the middle ear.

What the case report describes

The report details a 79-year-old man who lost approximately 200 pounds after starting semaglutide therapy. He later presented with intermittent bilateral aural fullness and autophony (an abnormal awareness of his own voice or breathing), without pain, vertigo, or other systemic symptoms. Otoscopic examination was unremarkable and prior tympanometry showed normal middle ear pressure, ruling out the more common obstructive form of Eustachian tube dysfunction. Based on the symptom pattern and exam findings, the clinical team diagnosed patulous Eustachian tube dysfunction (PETD) — a condition in which the Eustachian tube, which normally stays closed except when equalizing pressure, remains abnormally open. He was managed conservatively, with hydration, intranasal saline, and avoidance of decongestants (which can worsen patulous symptoms, unlike the obstructive form where they help).

Why rapid weight loss can affect the Eustachian tube

PETD is an uncommon diagnosis, and rapid weight loss is already a recognized risk factor for it, independent of how the weight loss was achieved. The mechanism proposed in the literature centers on peritubal fat: a layer of fatty tissue that cushions and helps hold the Eustachian tube closed at rest. When someone loses fat mass quickly and substantially, that supportive cushion can thin out, leaving the tube abnormally patent. The authors frame their case within a broader pattern they see coming: as GLP-1 receptor agonists like semaglutide produce larger and faster weight reductions in a growing population of patients, clinicians should expect to see more of the secondary, structural effects of rapid fat loss — effects that were rare simply because rapid, sustained weight loss of this magnitude used to be rare.

What this means for semaglutide research

A single case report doesn’t establish incidence, and it doesn’t prove that semaglutide itself — as opposed to the rate and amount of weight lost — is the causal factor. Case reports serve a narrower but still useful function in the literature: they flag a plausible clinical association early, before it shows up in larger datasets, so that both clinicians and researchers know to watch for it. For anyone tracking the semaglutide research landscape, this adds a specific, mechanistically grounded item to the growing list of downstream effects tied to rapid, large-scale weight loss — alongside more familiar ones like loose skin, gallstone risk, and muscle mass loss. It’s a useful example of how a drug’s primary mechanism (appetite suppression, slowed gastric emptying) can produce effects several steps removed from the GLP-1 receptor itself, simply as a consequence of how much and how fast the body’s composition changes.

Further reading

Burmeister JR, Jawad M, Zazay I, Kobernick A. “Patulous Eustachian tube dysfunction following rapid weight loss associated with semaglutide use: A case report.” SAGE Open Medical Case Reports. 2026;14:2050313X261486164. PubMed: 42694263 — DOI: 10.1177/2050313X261486164